anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Prolonged acting gonadotropic hormone preparations suitable for injection consist of an aqueous vehicle containing a gonadotropin obtained from urine, and an oxide, hydroxide or salt of zinc, the said substances forming an adsorption complex which is sparingly soluble in water at a pH between 6 and 8.  The gonadotropin is preferably chorionic, menopausal or postmenopausal.  Some of the zinc compound may be replaced by an oxide, hydroxide or salt of aluminium. The preparation may include an isotoniser, e.g. sodium chloride, and a preservative, e.g. a lower alkyl ester of p-hydroxy-benzoic acid. Other optional ingredients include plasma proteins, polyvinylpyrrolidone and gelatin.
The subjects in NMES priming with MCE group will receive the NMES using interferential mode (6000 Hz, beat frequency 20-50 Hz, scanning effect) on bilateral LM. The intensity will be set at the subject's maximum tolerance. Stimulation will be set at 10 seconds on and 60 seconds off to minimize muscle fatigue. The total NMES time is 20 minutes. After that, the subjects will receive 20-minute MCE.
The study targets a key gap in cardiac amyloidosis diagnosis by systematically evaluating the histopathological incidence of the disease using chest wall fat pad biopsies-tissue that is typically discarded during the implantation of cardiac devices like pacemakers, ICDs, and CRT-D/Ps. Standard surgical procedures are adhered to, ensuring minimal additional risk to patients. The collected tissue samples are analyzed by the HCA pathology laboratory to detect amyloid deposits, thereby potentially identifying amyloidosis in a non-invasive manner. In addition to the primary endpoint of histopathological diagnosis, the study retrospectively aims to validate a predictive model that incorporates a wide range of data to streamline the identification of patients at high risk for cardiac amyloidosis. Strict measures are in place to protect patient confidentiality and data security. By potentially improving diagnostic efficiency, this research could contribute to earlier detection and treatment strategies, thus improving patient outcomes for those at high risk of this life-threatening condition.
PCT No. PCT/US93/10555 Sec. 371 Date Jul. 14, 1995 Sec. 102(e) Date Jul. 14, 1995 PCT Filed Oct. 29, 1993 PCT Pub. No. WO94/09818 PCT Pub. Date May 11, 1994Criteria for identifying potential B cell superantigens are disclosed, together with a method for determining whether these candidate antigens have B cell superantigenic activity. Methods for constructing and using a vaccine including B cell superantigens are also disclosed. Identification is based on characterizing the structure of Ig binding sites which interact with the candidate antigen assessment of Ig V region diversity on binding of candidate and conventional antigens, confirmation of sAg activity in interactions between candidate antigens and whole cells, confirmation of whether the candidate antigen induces B cell mitogenesis, determination of the earliest point in B cell development where cellular co-factors are required for sAg activity and, for reference, determination of V region usage in responder populations. Once a B cell superantigen is characterized, it is purified and conjugated by chemical means to a polysaccharide or glycoprotein component from a microbial capsule, cell wall, envelope or other component preferably using components which stimulate production of antibodies with the same V region restriction as antibodies whose production is stimulated by the B cell superantigen.
For a safe swallowing tongue muscles must function properly and larynx should replace superoanterior to close trachea via stretching cricopharyngeal muscle. In this context, approximation of thyroid cartilage and larynx is important for swallowing. These mechanisms are impaired in stroke, Parkinson's disease, traumatic brain injury, and neuromuscular disorders thus resulting oropharyngeal dysphagia. Clinical examination may be used for assessing dysphagia in those patients however reliability of this method is controversial and videofluoroscopic study is considered as gold standard for assessing dysphagia. Ultrasound is used to assess swallowing functions since 1970s however, the studies commonly focused on tongue thickness and functions. Due to advances in technology besides tongue thickness, ultrasonography may practically demonstrate how larynx and thyroid cartilage approximate and hor larynx moves anteriorly. In literature, three methods came to forefront as evaluation methods for dysphagia: 1) approximation of thyroid cartilage and hyoid bone (THA), 2) tongue thickness in rest (TT), and 3) hyoid bone anterior replacement (HAR). In previous studies, the efficiency of THA for assessing dysphagia via videofluoroscopic study has been demonstrated. However other methods have not been evaluated in dysphagic patients with stroke. Ultrasonography, as a cheap, portable and non-invasive method, is a promising for assessing dysphagia in patients with stroke. In this context, this study aims to test the reliability and efficacy of these three methods via ultrasound in dysphagic stroke patients and test the performance of ultrasound compared to videofluoroscopy.
Participants performed a High intensity interval exercise (HIIE) bout which includes 10 x 1 min at 90% maximum heart rate (HRmax) with 5 min warm up and 5 min cool down at 50watts (low state steady cycling). 90mins following the exercise bout participants will undergo another oral glucose tolerance test.
The invention relates to new medical application of cedrol (CE), in particular to new application thereof in preparing medicaments for relieving pain and treating arthritis. The cedrol is alpha-cedrol, beta-CE or raceme of the two in any proportion, and the total effective dose of the cedrol is between 1 and 100 mg/kg/d. The CE is extracted from natural plants extensive in sources. The invention adopts rat-paw chondrus inflammation-inducing method and adjuvant arthritis to observe the anti-inflammatory effects of the CE, and results show that the CE has obvious effect of inhibiting nonspecific inflammation reaction caused by carrageenin and also has remarkable effect of treating and preventing the adjuvant arthritis. The invention adopts a tail-flick method to observe the analgesic effects of the CE, and results show that the CE has remarkable analgesic effects on the light-heat stimulated tails of rats. The invention provides a raw material for anti-inflammatory and analgesic drugs, which is exact in therapeutic effects, safe, convenient and extensive in sources, and can be combined with one or more pharmaceutically acceptable carriers so as to prepare a cedrol pharmaceutical composition or preparation.
Subjects eligible for the study will be ticagrelor naïve patients with NSTEMI presenting at the emergency room. Upon arrival to the emergency room written informed consent will be obtained before the patients receive their 180 mg loading dose of ticagrelor, as prescribed by the responsible physician.
Nocardiosis has caused high mortalities among fish cultures; however, the effects of Nocardia infections in the fish gastrointestinal microbiota are unknown. In this research, tilapia was infected with Nocardia sp., to analyze the effect of infection on the gastrointestinal microbiota. Tilapia infected with Nocardia sp. reported a 46 % survival (100 % in non-infected). Moreover, the infection caused severe damage to the stomach microbiota, with a loss of diversity and a significant increase of Proteobacteria (94.8 %), resulting in a negative correlation network between Proteobacteria and other important phyla. Nocardia sp. is an emerging pathogen capable of inducing dysbiosis and causing significant mortalities.
Nicotinamide riboside (NR) and pterostilbene oral capsules 250mg/50mg (Step 1) twice daily for 2 days. If the study progresses to Steps 2, 3, and 4, then 2x, 3x, and 4x the doses in Step 1 will be administered.
The objective of this longitudinal clinical study will be to evaluate the effect of dental treatment on individuals who practice physical activities through physical parameters of strength, speed and resistance. According to an initial survey, about 120 individuals should be examined. Clinical parameters such as decayed, lost and / or filled dental index and periodontal parameters such as probing depth (PS), clinical level of insertion (NCI), plaque index (IP) and bleeding index (IS) will be evaluated . Physical tests of strength, speed and resistance should be performed and periodontal therapy should be performed according to the needs presented by each individual. After 90 days, new clinical examinations and physical tests should be performed. The results obtained should be tabulated and analyzed. The investigators believe that individuals with oral inflammation / infection, the physical performance should be higher after performing periodontal therapy. Pro inflammatory cytokines present in high concentrations in the presence of periodontal disease can influence fatigue and difficulty in recovering from injuries, variables so important in an athlete's life.
The leading cause of mortality worldwide is atherosclerotic cardiovascular disease. Atherosclerotic plaques are well known to originate early in the childhood. Identifying hyperlipidemia in early childhood creates an opportunity to prevent major cardiovascular events in adults. Children with identified risk factors are at an increased risk of developing cardiovascular incidents in later life. This article emphasizes the diagnosis and management of pediatric hyperlipidemia with reference to the recent guidelines. In terms of etiology pediatric hyperlipidemia are divided into primary and secondary causes. The mainstay of management includes high-risk target screening, early risk factor identification and lifestyle modifications in vulnerable population. Drug therapy is recommended in primary hyperlipidemia and in children with no response to lifestyle changes.
NEW MATERIAL:The compound of formula I (R is H or lower alkyl) and its salt. EXAMPLE:2-[4-(trans-2-Hydroxycyclohexylmethyl)phenyl]propionic acid. USE:An analgesic and anti-inflammatory agent. It exhibits strong analgesic, anti- inflammatory and immuno-regulating activities. Dose: 50-300mg/kg daily for adult by oral administration in one or several divided doses. PREPARATION:The compound of formula I which is a mixture of cis- and trans- isomers can be prepared e.g. by reducing the compound of formula II with a reducing agent such as sodium cyanoborohydride in an inert organic solvent under ice-cooling or near the boiling point of the solvent for 10min - 3hr, if necessary adjusting the pH of the reaction liquid to about 3. The mixture can be separated into the cis-isomer and the trans-isomer by high performance liquid chromatography to obtain the desirable transisomer of the compound of formula I .
1. An amorphous form of 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-(2-piperidinylethoxy)benzoyl] benzo[b]thiophene of formula I   or pharmaceutically acceptable solvate thereof. 2. A process for preparing an amorphous form of 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-(2-piperidinylethoxy)benzoyl] benzo[b]thiophene of formula I   or pharmaceutically acceptable solvate thereof, which comprises preparing a solution of a crystalline form of a compound of formula I in a suitable solvent, and then spray drying said solution to recover an amorphous form of a compound of formula I. 3. The process of claim 2 wherein said suitable solvent is a mixture of methanol and water. 4. The process of claim 2 and of claim 3 wherein said spray drying is effected in the presence of an inert gas. 5. A pharmaceutical formulation comprising a compound according to Claim 1 in combination with a pharmaceutically acceptable carrier, diluent, or excipient. 6. A method for the inhibition of bone loss or bone resorption which comprises administering to a patient in need thereof a compound according to Claim 1. 7. The method according to Claim 6 wherein said bone loss or bone resorption occurs as a result of menopause or ovariectomy. 8. A method of inhibiting serum cholesterol levels which comprises administering to a patient in need thereof a compound according to Claim 1. 9. A method of alleviating the symptoms of post-menopausal syndrome which comprises administering to a patient in need thereof a compound according to Claim 1. 10. A method according to Claim 9 wherein said symptom of the post-menopausal syndrome pathological condition is osteoporosis. 11. A method according to Claim 9 wherein said symptom of the post-menopausal syndrome pathological condition is a cardiovascular disease. 12. A method according to Claim 11 wherein said cardiovascular disease is hyperlipidemia. 13. A method according to Claim 9 wherein said symptom of post-menopausal syndrome pathological condition is estrogen-dependent cancer. 14. A method according to Claim 13 wherein said estrogen-dependent cancer is breast or uterine cancer. 15. A method for alleviating the symptoms of uterine fibroid disease which comprises administering to a patient in need thereof a compound according to Claim 1. 16. A method for alleviating the symptoms of endometriosis which comprises administering to a patient in need thereof a compound according to Claim 1. 17. A method for alleviating the symptoms of aortal smooth muscle cell proliferation which comprises administering to a patient in need thereof a compound according to Claim 1. 18. A method for alleviating the symptoms of restenosis which comprises administering to a patient in need thereof a compound according to Claim 1.
An oral composition, suitable as a hypoglycemic agent, includes an isolate from the leaves of Gymnema sylvestre, having a specified molecular weight. The isolate has a molecular weight at least about 3000 Daltons as determined by molecular weight cut-off filtration. Glucose metabolism in a human patient can be regulated by dosage forms that contain the aforesaid isolate from the leaves of Gymnema sylvestre, in combination with a non-metabolizable, water-swellable polysaccharide such as the exudate of Sterculia urens, and a water-soluble polysaccharide such as guar gum. Optionally, the present oral compositions can include a physiologically acceptable calcium source, a physiologically acceptable metal carbonate salt, a physiologically acceptable chromium salt, and/or a physiologically acceptable vanadium compound. In addition, antioxidants such as ascorbic acid, cholecalciferol, d-α-tocopherol, the carotenoids, lycopene, lutein, and the like, can be included as well. The present compositions are useful for amelioration of cholesterolemia, obesity, chronic complications of diabetes and prophylaxis for patients predisposed to the foregoing.
Circulating lactate is a fuel source for liver metabolism but may exacerbate metabolic diseases such as nonalcoholic steatohepatitis (NASH). Indeed, haploinsufficiency of lactate transporter monocarboxylate transporter 1 (MCT1) in mice reportedly promotes resistance to hepatic steatosis and inflammation. Here, we used adeno-associated virus (AAV) vectors to deliver thyroxin binding globulin (TBG)-Cre or lecithin-retinol acyltransferase (Lrat)-Cre to MCT1fl/fl mice on a choline-deficient, high-fat NASH diet to deplete hepatocyte or stellate cell MCT1, respectively. Stellate cell MCT1KO (AAV-Lrat-Cre) attenuated liver type 1 collagen protein expression and caused a downward trend in trichrome staining. MCT1 depletion in cultured human LX2 stellate cells also diminished collagen 1 protein expression. Tetra-ethylenglycol-cholesterol (Chol)-conjugated siRNAs, which enter all hepatic cell types, and hepatocyte-selective tri-N-acetyl galactosamine (GN)-conjugated siRNAs were then used to evaluate MCT1 function in a genetically obese NASH mouse model. MCT1 silencing by Chol-siRNA decreased liver collagen 1 levels, while hepatocyte-selective MCT1 depletion by AAV-TBG-Cre or by GN-siRNA unexpectedly increased collagen 1 and total fibrosis without effect on triglyceride accumulation. These findings demonstrate that stellate cell lactate transporter MCT1 significantly contributes to liver fibrosis through increased collagen 1 protein expression in vitro and in vivo, while hepatocyte MCT1 appears not to be an attractive therapeutic target for NASH.
Renal interstitial fibrosis (RIF) is a significant pathological change in diabetic kidney disease (DKD) that can be induced by endothelial-to-mesenchymal transition (EndMT). Lymphangiogenesis, mediated by the vascular endothelial growth factor-C (VEGF-C)/vascular endothelial growth factor receptor-3 (VEGFR-3) pathway, plays a crucial role in the development of RIF in DKD. Although numerous studies have demonstrated the efficacy of empagliflozin in treating renal injury, its effects on lymphangiogenesis in DKD-related RIF and the underlying mechanisms remain unclear. In the present study, significant lymphangiogenesis was assessed in the renal interstitium of patients with DKD. We subsequently explored the relationship between DKD-related RIF and lymphangiogenesis in mouse models, high-glucose (HG)-stimulated renal HK-2 cell lines, and human lymphatic endothelial cells (hLECs). Additionally, we evaluated the effects of empagliflozin on these processes. The results revealed that HG induces lymphangiogenesis, which exacerbates RIF by promoting inflammatory responses. Furthermore, hLECs directly contributed to the progression of DKD-related RIF through EndMT. Further analysis revealed that tubular epithelial cells (TECs) act as effector cells for VEGF-C, with the epithelial-to-mesenchymal transition (EMT) of TECs occurring concurrently with the EndMT of lymphatic vessels. Empagliflozin inhibited RIF in DKD by suppressing the VEGF-C/VEGFR3 pathway and reducing lymphangiogenesis. In conclusion, this study elucidates the interplay between lymphangiogenesis, EndMT, and RIF in DKD and provides new insights into the mechanism by which empagliflozin treats DKD.
Stage1:Patient information form, follow-up form, State Continuity Anxiety Scale, Richard Campbell Sleep Scale were filled. Stage 2:On the second day of the surgery, at 20:00 in the evening, they were asked to inhale 2-3 drops of bergamot essential oil, which was dripped onto the pillow pouches,at 21:00, and these bags were placed 10 cm away from the patient after 20 minutes. These bags were taken from the bedside of the patient at 08:00 in the morning.Stage 3:Before the evening application, the patient follow-up form, State-Continuity Anxiety Scale, Richard Campbell Sleep Scale were filled and they were asked to inhale 2-3 drops of bergamot essential oil, which was dropped on the pillow bags prepared at 20:00, and inhaled at 21:00. Afterwards, these sacs were placed 10 cm away from the patient.These sacs were taken from the bedside of the patient at 08:00 in the morning and the patient follow-up Form, State-Trait Anxiety Scale, Richards-Campbell Sleep Scale were filled.
Musculoskeletal disorders (MDs) represent a global health issue, which can lead to disability. Physical activity (PA) reduces pain and increases physical function among patients with MDs. To promote behavioural changes, it seems important to focus on modifiable factors, such as motivation. Thus, this review aims to assess effects of interventions targeting PA on motivation towards PA. Searches used terms referring to "physical activity", "motivation" and "chronic musculoskeletal disorders" on the databases PubMed, PsychINFO, MEDLINE, EMBASE, PEDro and Web of Science. All types of intervention-including but not limited to RCTs-were eligible for inclusion. Risk of bias was assessed with the Quality Assessment Tool for Studies with Diverse Designs (QATSDD). Among 6 489 abstracts identified, there were 387 eligible studies and 19 were included, reporting in total 34 effect sizes. The meta-analysis concerned 1 869 patients and indicated a small effect of interventions on change in motivation towards PA (d = 0.34; 95% CI [0.15; 0.54]; p < .01; k = 33). Behavioural interventions positively impact PA motivation in patients with MDs. In the literature, most studies focused on intervention's effect on fear of movement. Future research should assess other explicit motivational constructs, as well as implicit processes.
Hyperglycemia, hypercholesterolemia, and hypertriglyceridemia have been reported in patients taking everolimus at an incidence up to 75%, 86%, and 73%, respectively. The incidence of these Grade 3 and 4 laboratory abnormalities was up to 15% and up to 0.4%, respectively [see Adverse Reactions (6.1)] . In non-diabetic patients, monitor fasting serum glucose prior to starting TORPENZ and annually thereafter. In diabetic patients, monitor fasting serum glucose more frequently as clinically indicated. Monitor lipid profile prior to starting TORPENZ and annually thereafter. When possible, achieve optimal glucose and lipid control prior to starting TORPENZ. For Grade 3 to 4 metabolic events, withhold or permanently discontinue TORPENZ based on severity [see Dosage and Administration (2.9)] .
Solid melts of acetoacetic acid aryl amide derivatives (I) are new. The melts contain 5-15 wt. % water. Solid melts of acetoacetic acid aryl amide derivatives of formula (I) are new. The melts are ready to use industrially and contain 5-15 wt. % water. R = H or one or more substituents selected from alkyl, alkoxy or halo. An Independent claim is also included for preparation of (I).
The invention relates to a magnetic nano sheet-shaped hydroxyapatite and a preparation method and application thereof. The magnetic nano sheet-shaped hydroxyapatite is prepared from calcium nitrate, diammonium hydrogen phosphate, ferric chloride, ferrous chloride and sodium hydroxide by using sodium dodecyl sulfate as a template agent and adopting an in-situ template synthesizing method. The magnetic nano sheet-shaped hydroxyapatite has an orderly lamellar nano structure, and the interlayer space is 3.1 nm. The composition of nano granulated ferroferric oxide and nano lamellar hydroxyapatite is realized, and the ferroferric oxide has uniform distribution and no agglomeration. The compound material has superparamagnetism, and the saturation magnetic moment is 13.21emu/g. Because used reagents are a common reagent, the magnetic nano sheet-shaped hydroxyapatite has the advantages of low cost and no pollution.
PROBLEM TO BE SOLVED: To prepare an incense whose smell changes according to burning by serially arranging a plurality of perfumery materials to introduce a plurality of perfumes in one incense stick. SOLUTION: An incense 1 whose smell changes is prepared by serially arranging a plurality of perfumery materials 2 having different smells. The perfumery materials 2 are preferably arranged continuously or with spaces between them. Further, it is preferable that a burning time of each perfumery material 2 is set in such a manner that time can be managed by the change of smell, or smells of perfumery materials are selected in such a manner that the change of smell brings physiological or psychological change. When the incense 1 is burned from one end, the smell corresponding to a perfumery material 2 which is burning is dispersed, and further the dispersed smell serially changes according to the passage of burning time corresponding to the length of a perfumery material 2.  Therefore, when perfumery materials 2 are arranged with a certain purpose, the smell can be changed according to the purpose.